P-148: Real-life analysis of the multiple myeloma patient’s survival in a third-level hospital

Background Multiple myeloma (MM) constitutes approximately 10% of haematological malignancies, with a median age at diagnosis of 65 years. Patient survival has improved considerably over the last 20 years with the introduction of new drugs. In 1999, the first immunomodulatory drug, thalidomide, was approved, followed by lenalidomide in 2005 and pomalidomide in 2013. In 2003, proteosome inhibitors such as bortezomib were introduced and carfilzomib in 2014. In 2015, anti-CD38 monoclonal antibodies such as daratumumab were added to the treatment schemes. We have analyzed the impact on the outcome of the introduction new drugs for MM in the last 20 years in our institution. Methods A total of 862 patients diagnosed with symptomatic multiple myeloma between 1999 and 2020 in a tertiary care hospital in Spain, Hospital 12 de Octubre in Madrid, were retrospectively analysed. Survival by age was evaluated over the years, establishing three groups: 1999-2005, 2005-2015 and 2015-2020. Kaplan-Meier analysis was used for analyzing overall survival, and differences between groups were tested for statistical significance using the log-rank test. Results A total of 862 patients were included in the study. There were 409 men (47.45%) and 453 women (52.55%). The median age at diagnosis was 69 years. Among the group of patients younger than 65 years, the median survival among patients treated between the period 1999 to 2005 was 49.28 months (16.86-81.70; 95%); 78.42 months (49.83-107.01; 95%) between the years 2005 to 2015 and the median is not reached between the years 2015 to 2020 (p=0.001). Equally significantly, patients younger than 75 years have improved survival over the years. Median survival among patients treated between 1999 and 2005 was 43.43 months (23.86. 63.00; 95%); 58.80 months (43.38-74.23; 95%) between 2005 and 2015 and the median is not reached between 2015 and 2020 (p Conclusion The introduction of new agents in the treatment of multiple myeloma has transformed the natural history of the disease, achieving long survival times in younger patients. Thus, it is essential to continue to advance and develop new therapies, as has been the case in recent years with the emergence of antiBCMA therapies.